SCHEDULE 13G 0001230239 XXXXXXXX LIVE Class A Common Stock, par value $0.00001 per share 06/30/2025 0001673743 Hinge Health, Inc. 433313103 455 MARKET STREET 7TH FLOOR SAN FRANCISCO CA 94105 Rule 13d-1(d) Alkeon Capital Management LLC DE 0.00 1591104.00 0.00 1591104.00 1591104.00 N 5.7 IA OO Includes 1,215,093 shares of Class A Common Stock (as defined in Item 2(a)) issuable upon conversion of Class B Common Stock (as defined in Item 2(a)). Panayotis D. Sparaggis X1 0.00 1591104.00 0.00 1591104.00 1591104.00 N 5.7 HC IN Includes 1,215,093 shares of Class A Common Stock issuable upon conversion of Class B Common Stock. Hinge Health, Inc. 455 Market Street, Suite 700, San Francisco, CA 94105 This statement is filed by: (i) Alkeon Capital Management LLC ("Alkeon"), a Delaware limited liability company and the investment manager to certain funds (the "Alkeon Funds"), with respect to the shares of Class A Common Stock, par value $0.00001 per share ("Class A Common Stock") of Hinge Health, Inc., a Delaware corporation (the "Company") directly held by, and the shares of Class A Common Stock issuable upon conversion of the shares the Company's Class B Common Stock, par value $0.00001 per share (the "Class B Common Stock") directly held by, the Alkeon Funds; and (ii) Panayotis D. Sparaggis ("Mr. Sparaggis"), the Founder and Managing Director of Alkeon, with respect to the shares of Class A Common Stock directly held by, and the shares of Class A Common Stock issuable upon conversion of the shares of Class B Common Stock directly held by, the Alkeon Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the securities reported herein. The address of the business office of each of the Reporting Persons is 350 Madison Avenue, 20th Floor, New York, NY 10017. The Investment Manager is a Delaware limited liability company. Mr. Sparaggis is a citizen of the United States. Y The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 26,799,441 shares of Class A Common Stock outstanding as reported in the Company's Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on May 23, 2025, and in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 23, 2025, after giving effect to the completion of the offering and the full exercise of the underwriters' over-allotment option, all as described therein, and assumes the conversion of the shares of Class B Common Stock held by the Alkeon Funds. 5.7% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Y N See Item 2(a). The Alkeon Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, shares of Class A Common Stock. Y Y Y Y Exhibit 99.1: Joint Filing Agreement Alkeon Capital Management LLC /s/ Jennifer Shufro 08/13/2025 Panayotis D. Sparaggis /s/ Panayotis D. Sparaggis 08/13/2025